HELA-Exos exhibit potent antitumor activity in both a mouse model and human organoids of breast cancer by promoting the activation of cDC1s in situ and thus improving the subsequent tumor-reactive CD8+ T cell responses. The gene discussed is CD8A; the disease is breast carcinoma.